Trending Topic

< 1 min

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

This corrects the article: “Ioannou A. Evolution of Disease-modifying Therapy for Transthyretin Cardiac Amyloidosis. Heart International. 2024;18(1):30-37”. Two typography errors were included incorrectly due to an editorial error. In Table 1, “eplontersen” was incorrectly written as “eplomtersen”. This has been corrected in the text. In the section “Eplontersen”, the administration schedule should be written as […]

Role of optimal medication given to patients with hypertension and ischemic heart disease prior to an acute coronary syndrome

Călin Pop, Roberta Florescu, Claudia Matei, Lavinia Pop, Viorel Manea, Coralia Cotoraci, Liana Mos, Antoniu Petris
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF
Published Online: Aug 23rd 2018 Heart International. 2017;12(1):e18-e23 DOI: https://doi.org/10.5301/heartint.5000237
Select a Section…
1

Abstract

Overview

Introduction.
Administering optimal cardiovascular medication (OCM) to patients with hypertension (HBP) and
ischemic heart disease (IHD) lowers cardiovascular morbidity and mortality.
The main objective of this study was to compare in-hospital cardiac mortality among patients with HBP and/or
IHD, treated or untreated with OCM, who developed a first episode of acute coronary syndrome (ACS).
Methods.
The study was carried out retrospectively and included patients admitted with a first episode of ACS
between 2013 and 2016. The patients were divided into three groups: those with HBP, IHD, and a history of HBP +
IHD. Patients were then divided into two subgroups: subgroup A consisted of patients undergoing optimal anti-
ischemic and/or antihypertensive therapy, while subgroup B consisted of patients without OCM.
Results.
This analysis comprised 1096 patients. Mean age was 64.3 ± 18 years. There were 581 patients in subgroup A – 53%, and 515 patients in subgroup B – 47%. Total cardiac mortality was 9.98%, different depending
on the groups and subgroups studied: HBP group total – 7%, subgroup A – 5.1%, significantly lower compared
to subgroup B – 9.4% (p = 0.05); IHD group total – 12.2%, subgroup A – 9.07%, significantly lower compared to
subgroup B – 15.8% (p = 0.05); HBP + IHD group total – 14.35%, subgroup A – 9.9%, significantly lower compared
to subgroup B – 18.8% (p = 0.05).
Conclusions.
The lack of OCM in patients with HBP and/or IHD is correlated to a significant increase in in-hospital
cardiac mortality among patients who develop a first-episode ACS.

Keywords

Acute coronary syndrome, Cardiac mortality, Hypertension, Ischemic heart disease, Optimal cardio – vascular medication

2

Article Information

Disclosure

Financial support: No grants or funding have been received for this study.

Correspondence

Călin Pop George Cosbuc Street nr 31 Baia Mare, Romania medicbm@yahoo.com

3

Further Resources

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup